Andersons pediatric cardiology 1943

Immunol.1989;83(2Pt1):486–494.
146.KolczJ,Tomikiewicz-PajakL,WojcikE,
PodolecP,SkalskiJ.Prognosticsignificanceand
correlationsofneurohumoralfactorsinearlyand
latepostoperativeperiodafterFontanprocedure.
InteractCardiovascThoracSurg.
2011;13(1):40–45.
147.CzarnowickiT,GonzalezJ,ShemerA,etal.
Severeatopicdermatitisischaracterizedby
selectiveexpansionofcirculatingTH2/TC2and
TH22/TC22,butnotTH17/TC17,cellswithin
theskin-homingT-cellpopulation.JAllergyClin
Immunol.2015;136(1):104–115.
148.MorsheimerMM,RychikJ,ForbesL,etal.Risk
factorsandclinicalsignificanceoflymphopenia
insurvivorsoftheFontanprocedureforsingleventriclecongenitalcardiacdisease.JAllergy
ClinImmunolPract.2016;4:491–496.
149.CheungYF,TsangHYH,KwokJSY.
Immunologicprofileofpatientswithproteinlosingenteropathycomplicatingcongenitalheart
disease.PediatrCardiol.2002;23(6):587–593.
150.MagdoH,StillwellT,GreenhawtM,etal.
ImmuneabnormalitiesinFontanprotein-losing
enteropathy:acase-controlstudy.JPediatr.
2015;167:331–337.
151.MullerC,WolfH,GottlicherJ,ZielinskiC,Eibl


M.Cellularimmunodeficiencyinprotein-losing
enteropathy.PredominantreductionofCD3+
andCD4+lymphocytes.DigDisSci.
1991;36(1):116–122.

152.AnneP,DuW,MattooTK,ZilbermanMV.
NephropathyinpatientsafterFontanpalliation.
IntJCardiol.2009;132:244–247.
153.SharmaS,RuebnerR,FurthS,etal.Assessment
ofkidneyfunctioninsurvivorsfollowingFontan
palliation.CongenitHeartDis.2016;11:630–
636.
154.AssenzaG,GrahamD,LandzbergM,etal.
MELD-XIscoreandcardiacmortalityor
transplantationinpatientsafterFontansurgery.
Heart.2013;99:491–496.
155.AllenKY,DowningTE,GlatzAC,etal.Effect
ofFontan-associatedmorbiditiesonsurvival
withintactFontancirculation.AmJCardiol.
2017;119(11):1866–1871.
156.AvitabileCM,LeonardMB,ZemelBS,etal.
Leanmassdeficits,vitaminDstatusand
exercisecapacityinchildrenandyoungadults
afterFontanpalliation.Heart.
2014;100(21):1702–1707.
157.GoldbergDJ,ShaddyRE,RavishankarC,
RychikJ.ThefailingFontan:etiology,diagnosis
andmanagement.ExpertRevCardiovascTher.


2011;9(6):785–793.
158.GoldbergDJ,SurreyLF,GlatzAC,etal.Hepatic
fibrosisisuniversalfollowingFontanoperation,
andseverityisassociatedwithtimefrom
surgery:aliverbiopsyandhemodynamicstudy.

JAmHeartAssoc.2017;6(5).
159.RychikJ,GoldbergDJ.Lateconsequencesofthe
Fontanoperation.Circulation.
2014;130(17):1525–1528.
160.SurreyLF,RussoP,RychikJ,etal.Prevalence
andcharacterizationoffibrosisinsurveillance
liverbiopsiesofpatientswithFontancirculation.
HumPathol.2016;57:106–115.
161.RychikJ,VeldtmanG,RandE,etal.The
precariousstateoftheliverafteraFontan
operation:summaryofamultidisciplinary
symposium.PediatrCardiol.2012;33(7):1001–
1012.
162.SchwartzMC,GlatzAC,DanielsK,etal.
Hepaticabnormalitiesarepresentbeforeand
earlyaftertheFontanoperation.AnnThorac
Surg.2015;100(6):2298–2304.
163.SchwartzMC,SullivanLM,GlatzAC,etal.
Portalandsinusoidalfibrosisarecommonon
liverbiopsyafterFontansurgery.Pediatr
Cardiol.2013;34(1):135–142.
164.SurreyLF,RussoP,RychikJ,etal.Definingthe